1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
NeutriSci International Inc.

NeutriSci International Inc.

NRXCF
NeutriSci International Inc.US flagOther OTC
0.00
USD
- -
- -
653,980.00Market Cap
NeutriSci International Inc.
NRXCF
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2008
2009
2010
2011
2012
2013
2014
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
FRC
0.2
0.1
0.15
0.07
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.98
-0.64
-0.54
-0.66
-0.77
2.43
-0.05
- -
-0.09
-0.04
-0.03
-0.02
-0.01
-0.01
-0.01
- -
- -
Basic EPS, GAAP
-0.98
-0.55
-0.36
-0.39
-0.4
-0.35
-0.04
- -
-0.05
-0.04
-0.02
-0.02
-0.01
-0.01
-0.01
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-3.54
-4.04
-4.53
-5.08
-5.81
-3.38
-1.5
- -
-0.58
-0.43
-0.04
-0.03
-0.03
-0.03
-0.03
-0.03
-0.03
Book Value per Share
-0.28
-0.87
-1.39
-2.04
-2.8
-0.22
0.12
- -
0.02
0.01
- -
- -
- -
- -
- -
- -
-0.01
Tangible Book Value per Share
3
3
3
3
3
3
8
- -
41
60
82
102
116
143
159
166
178
Basic Weighted Avg Shares
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-483
-579.19
-254.81
-623.96
- -
- -
- -
- -
-8,750.91
-2,042.8
-1,385.6
-2,753.5
-1,710.67
-2,607.24
-1,716.09
-150.81
-841.3
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-3
-2
-2
-2
-2
8
- -
- -
-4
-3
-2
-2
-2
-2
-2
-1
-1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-482.56
-662.43
-360.16
-982.07
- -
- -
- -
- -
-15,505.14
-2,046.12
-1,404.81
-2,882.67
-1,670.71
-2,618.34
-1,943.53
-168.37
-921
Profit Margin (%)
-1
-3
-5
-7
-9
-1
1
1
1
1
- -
- -
- -
- -
- -
-1
-1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
-1
-3
-5
-7
-9
-1
1
1
1
1
- -
- -
- -
- -
- -
-1
-1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'23
Jun'23
Sep'23
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
178
178
178
Market Capitalization
2
2
1

Working Capital

FRC

•

in mil. unless spec.
Mar'23
Jun'23
Sep'23
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
71.76%
211.99%
1,196.16%
Free Cash Flow
- -
-17.31%
-85.12%
Net Income, GAAP
- -
-13.89%
-50.98%
Sales/Revenue/Turnover
- -
84.62%
465.86%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
-0.01
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
Eve & Co Incorporated (EEVVF)
ShanXi C&Y Pharmaceutical Group Co., Ltd. (300254.SZ)
IOL Chemicals and Pharmaceuticals Limited (IOLCP.NS)
Grown Rogue International Inc. (GRIN.CN)
Leef Brands Inc. (LEEF.CN)
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (YIHCF)
Business
NeutriSci International Inc. develops, formulates, produces, and markets nutraceutical products for B2B partners in the health and wellness industry; core offerings include neuenergy energy tablets for enhanced focus and mental clarity, effervescent functional mushroom tablets, and sublingual tabs such as Dablets and Zenstix utilizing patent-pending Cryolization Technology for rapid bloodstream delivery of natural ingredients including cannabinoids; the company also provides contract manufacturing, co-branding, private label services, and product development expertise incorporating proprietary IP. NeutriSci International operates production and research facilities including a dedicated site in Las Vegas, Nevada, with scalability for global distribution through retail storefronts, online channels, convenience stores, chain drug outlets, mass market retailers, and supermarkets; it serves markets in Canada, the United States, Germany, Japan, Europe, Asia, South America, and Australia. Founded in 2009 and headquartered in Vancouver, Canada, the company maintains strategic partnerships with entities including Tabletz LLC for Japanese distribution, THIC for European market entry, Cryopharm, LaSanta Botanicals, Nutritional High, Naturally Splendid, Thai Freeze Dry, and Scientus Pharma; recent developments encompass voluntary delisting from OTCQB in February 2022 to redirect capital, ongoing global B2B expansion, new product pipelines, and facility optimizations for higher margins.

Company News

APIChatGPT

  • accesswire.com

    NeutriSci Receives Additional Purchase Order and Deposit from Tabletz Distribution Partner

  • accesswire.com

    NeutriSci Arranges Strategic Financing with Tabletz and Exercise of Warrants

  • accesswire.com

    Neutrisci Provides Update on Tabletz Developments

  • accesswire.com

    Neutrisci Provides Update on Tabletz and Previously Announced Project Development

  • accesswire.com

    NeutriSci Provides Update On Biople Product Launch In Japan

  • accesswire.com

    Neutrisci Ships Tabletz Rush Order to #1 CBD Retailer in Japan

  • accesswire.com

    NeutriSci Completes R&D and Expands Product Selection to Include Beverages

  • accesswire.com

    NeutriSci and Pacwest Announce Technology and IP Arrangement for R&D Product Development

  • accesswire.com

    Neutrisci Announces Successful Completion of Phase 1 R&D Development of a Cannabinol Product

  • accesswire.com

    Neutrisci Receives Additional Order for Japanese Market

  • accesswire.com

    Neutrisci Announces New State-Of-The-Art Production and Research Facility in Las Vegas, Nevada, USA

  • accesswire.com

    NeutriSci: Harmonized Code Approval Received by TABLETZ LLC., in Japan